Palliative care - Teaching Clinic Flashcards

1
Q

Functional assessment metrics

A

Basic and instrumental Activities of daily living
- Basic: Dressing, Ambulation, Bathing, Eating, Transferring, Toileting
- Instrumental: Food prep, housekeeping, laundry, grocery shopping, using phone, managing medication, managing finances, using transport

ECOG performance status:
- ECOG <= 2: Asymptomatic, rarely a/w sudden death
- ECOG >= 3: Start of physical deterioration esp weight loss
- Higher ECOG = shorter median survival rate

Additional questions
Their ability to walk a half mile; stoop, kneel, or crouch; climb a flight of stairs; and do heavy housework, such as washing floors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Illness trajectories types

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ECOG performance status trajectory with cancer progression

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Predictors of life-expectancy of a cancer patient

A
  • Median survival rate: guide only, survival range is vast
  • Time to tumor growth (TTG)
  • tumor size ratio (TSR)
  • tumor growth rate (kG)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

WHO definition of palliative care

A

Palliative care is:
- Active care of patients
- Whose disease is not responsive to curative treatment
- Control of pain, psychological, social, spiritual problems
- Acheivement of best possible QOL for patient and their family
- Applied early in the course of the illness with anti-cancer treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cancer pain

  • Prevelance
  • Components of total pain
A

Prevalence
- 30-45% moderate to severe pain at diagnosis
- 65-90% pain at advanced disease

Total pain:
- Physical: cancer symptoms, treatment S/E, insomnia, chronic fatigue, cachexia, delirium
- Social: worry about family and friends, loss of job/ title/ income, Loss of social position, Feeling of abandonment and isolation
- Spiritual: point of life? purpose? God?
- Psychological: Anger at therapeutic failure and delays in diagnosis, disfigurement, fear of pain and death, helplessness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cancer pain

Physical assessment

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

WHO pain ladder

  • Define tiers
  • Standard drugs in each tier
  • Analgesic use recommendations
A

If pain occurs, there should be prompt oral administration of drugs in the following order:
1. non-opioids: Paracetamol 500-1000mg QID, NSAID conventional doses
2. then mild opioids: Tramadol 50-100mg QID; dihydrocodeine (e.g. DF118) 30mg Q4-6hrs
3. then strong opioids, until the patient is free of pain: Morphine (oral) 5mg Q4H PO, No ceiling dose

Recommendations:
- Oral route
- GIven on fixed dose schedule, not on as-need basis
- Dosage titrated against particular pain
- Adjuvant drugs should be used for specific pain etiologies
- Give laxatives (Senokot 2 tab nocte PO and/or lactulose 10ml TDS PO) for long-term opioid use
- Prescribe antiemetics to control nausea during the first week of opioid use: metoclopramide 10mg TDS or haloperidol 1.5mg - 3mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

List weak and strong opioids

A

Weak opioid
* Codeine
* Tramadol
* DF118 (Dihydrocodeine), oxycontin

Strong opioid
* Morphine
* Oxycodone
* Fentanyl
* Methadone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tramadol
- Dose
- PK
- S/E
- D/D interactions

A

Dose: 50-100mg TDS-QID PO
* For elderly max dose <300mg/day
* For patients with mild renal impairment: <200mg/day

Half life: 6 hours. Prolonged in liver failure
Kidney excretion of metabolite

Side effects:
* Nausea/vomiting, dizziness, sweatiness, dry mouth
* Constipation, convulsion (rare)
Drug interactions
* Tricyclic antidepressants (TCAs)
* Serotonin selective receptor inhibitors (SSRI)
* Monoamine oxidase inhibitors (MAOIs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Morphine
- Starting dose
- PRN dose
- Adjunct drugs

A

Starting dose: use short-acting morphine syrup first
* Morphine 5mg QID + 10 mg Nocte/zolpidem (or 5mg Q4H PO)

Consider 2.5mg Q4H in elderly patients or patients with marginal renal function

Always prescribe prn dose of morphine: 50-100% of regular dose, e.g.
* Morphine 5mg PO Q4H prn
* Morphine 2.5mg subcutaneous Q4H prn

Always prescribe laxative with opioid: Senokot 2 tab nocte PO, Lactulose 10ml BD-TDS PO

Antiemetics during the first week of opioid initiation: metoclopramide 10mg TDS, haloperidol 1mg - 2mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Titration of morphine

Factors that warrant titration
Typical dose levels

A

Increase or decrease morphine dose based on
* Patient’s pain score (do not aim for 0 score)
* The need of prn analgesics (as needed)
* Increase the regular dose every 2-3 days/ if severe pain
* Side effects profile: any signs of opioid toxicity, renal function, hydration status
* Consider decrease dose if tumor responded well to treatment (chemo/targeted therapy / radiation therapy) or toxicity significant
* Change to long-acting opioid (MST continuous tablet) if needed

Dose levels commonly used: e.g. 5mg Q4H ↔ 7.5mg ↔ 10mg ↔
15mg ↔ 20mg ↔ 30mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Morphine titration

Define satisfactory pain control
Titration ratio for oral morphine syrup to SC/ IV/ MST tablet

A

Satisfactory pain control level
* Pain score 0-3
* Need of prn morphine for breakthrough pain 0-2 times per day
* Patient can sleep well
* Patient’s subjective judgment

Conversion of oral to SC Morphine = 2:1
Conversion of oral to IV Morphine = 3:1
Conversion of morphine syrup to MST = 1:1
Onset time for oral morphine: 30min
Onset time for SC morphine: 15min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Morphine and renal impairment

  • Caution
  • Dosage
  • C/I
A
  • Active metabolite of morphine: morphine-6-glucuronide (M6G)
  • Accumulation of M6G occurs in patients with renal insufficiency
  • Patient with creatinine clearance / glomerular filtration rate <50ml/min should be initiated with morphine at 50% dosing with high caution. Specialist consultation is recommended
  • Use of morphine in patient with CrCl/GFR <10ml/min should be avoided
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

S/E of opioids

A

Early (72 hours)/ mild:
- Nausea / Vomiting, treat with prophylactic antiemetics
- Sedation/ drowsiness: transient, self-resolving 2-4 days
- Constipation: treate with laxative prophylaxis, increase dose or combo laxatives (not bulking agent)
- Pruritis: treat with anti-histamine
- Xerostomia: pilocarpine 2%, mouth care
- Urinary retention: resolve in a week

Severe:
- Opioid induced neurotoxicity: hyperalgesia, allodynia, agitation, delirium, hallucinations
- Myoclonus: early sign of neurotoxicity
- Respiratory suppression, decreased consciousness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Patients at high risk of opioid s/e
Signs of OD
Management of adverse effects

A

High risk: elderly, frail patient, marginal renal function, poor oral intake

OD:
- Pinpoint pupils, LOC, Shallow/ slow respiration, pale skin, cyanosis, snoring/ stretor (tongue obstruction)

Management:
- Withhold 1-2 doses
- Opioid rotation
- Consult pain specialist
- diluted naloxone bolus IV injection - 0.04mg/ml

17
Q

Fentanyl

  • Route of administration
  • Advantage
  • Disadvantage
  • Conversion with morphine
A

Route: Patch/ SC infusion

Advantage: Less constipating, less sedative, can be used in renal failure patients

Disadvantage: slow onset, very difficult to titrate

Conversion to morphine:
* 25mcg/hr = 4.2mg = 60-90mg oral morphine

18
Q

Methadone

  • Starting dose
  • Advantage
  • Disadvantage
A

Starting dose: as low as possible
Long t1/2: 30 hours, given Q12H, takes 1 week to reach static state

Advantage: Spare high dose morphine/ morphine washing effect; lower nephrotoxocity, better at neuropathic pain

Disadvantage: High dose (>40mg/day) causes fatal arrhythmia, difficult to titrate

19
Q

Palliative RT for pain control
- Indications
- Advantage
- Disadvantage

A

Indications:
- Uncomplicated bony met.
- Mediastinal obstruction, cough, hemoptysis
- Bleeding control in GIT, GUT, H&N, breast CA
- Control CNS symptoms in cerebral/ leptomeningeal met.

Advantage:
- Non-invasive
- Tolerable
- Brief treatment (1 day to two weeks)

Disadvantage:
- 70% effective
- Ionizing radiation

20
Q

Intraspinal opioid

Dose conversion
MoA
Indications

A

Intrathecal versus epidural opioid administration

Dose conversion: intrathecal to PO: 1mg to 300mg

Implanted programmable pump with different programming options

Less systemic side effects

Patient selection:
* intractable pain >5
* daily morphine consumption >200mg/day or intolerable side effects
* life expectancy >4-6 months

21
Q

Malignant spinal cord compression

Determinants of treatment modality

A

Spinal Instability Neoplastic Score (SINS):
- SINS > 7 indicate instability and surgical treatment e.g. kyphoplasty/ vertobroplasty

Tokuhashi score: Criteria of predicted prognosis:
- Total score 0-8 : <6m
- Total score 9-11: 6-12m
- Total sore 12-15: >12m

Surgery indicated:
■ Limited levels of cord compression
■ Minimal neurological impairment
■ Spinal instability (leading to mechanical and functional pain)
■ Previous radiotherapy which has been administered at the level of metastatic spinal cord compression

22
Q

Neurolytic blocks

  • Locations of blocks
  • MoA
A

Injection of alcohol or phenol to deaden the nerve causing pain
Celiac plexus block: Pancreatic CA, upper abdominal tumor

Ganglion impair block: Perineal pain

Superior hypogastric plexus block: Pelvic tumor

23
Q

Breathlessness in palliative care patients

  • ATS definition
  • Prevalence
  • Effects
A

Breathlessness: also termed Breathlessness, Dyspnea, Shortness of Breath, Chest tightness

ATS definition:
- subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity
- derives from interactions among multiple physiological, psychological, social, and environmental factors
- may induce secondary physiological and behavioral responses

Prevalence: Up to 70% patients with advanced cancer

Effect:
- On patient and family: disabling/ distressing, anxiety/ depression, anorexia, poor concentration, lower QoL, poorer prognosis
- Social: financial burden to healthcare, more adverse events in hospitals, need of sedation, more hospital admission

24
Q

Pathophysiology of breathlessless in palliative care patients

A
25
Q

Assessment of breathlessless in palliative care patients

A

Assess Total Pain: Physical, Spiritual, Psychological, social

Assess intensity of dyspnea: Physical:
- Visual analog scale (VAS), numerical rating scale (NRS): Score: 0-10
- Modified Medical Research Council (MRC) Dyspnea Scale

Psychological:
* Hospital Anxiety and Depression Scale (HADS)
* Brief Edinburgh Depression Scale (BEDS)

Social:
* Social support: carers
* Living environment
* Financial support

Spiritual Assessment: HOPE
* H: sources of hope, meaning, comfort, strength, peace, love,
connection
* O: Organised religion
* P: Personal spirituality and practices
* E: Effects on medical care and end of life care
Referral: Health care chaplain or person’s faith community leader

26
Q

Pharmacological treatment options for breathlessness in palliative care patients

A

Pharmacological options:
Opioids:
- reduce baseline/ post-treatment dyspnea score
- Starting dose oral morphine 2-3mg Q4H; or 25% of 4 hourly breakthrough analgesic dose prn in immediate release tablets (MST)

BDZs: 3rd line, benefit unclear
* Lorazepam 0.5mg Q4-6hr SL
* Diazepam 2-5mg nocte, BD or prn po
* Midazolam 5-20mg Q24H IV/ SC in EOL

Oxygen therapy: benefit unclear
- NIV
- Can cause dependence, discomfort, dry air, restrict mobility, fires, high cost

Bronchodilators

Corticosteroids: Dexamethasone 4-8mg po om

27
Q

Non-pharmacological treatment options for breathelessness in palliative care patients

A
  • High strength of evidence:neuro-electrical muscle stimulation, chest wall vibration
  • Moderate strength of evidence: Use of walking aids and breathing training
  • Facial cooling with fan
  • Positioning and pacing breathing (lean forward)
  • Anxiety reduction training: relaxation, mindfulness, self-hypnosis…
  • Education & Communication, lifestyle modifications
28
Q

When to do pharmocological vs non-pharmacological treatments for breathlessness

A
29
Q

Nausea and vomiting in cancer patients

  • Causes
  • Management
A

Causes:
* GI related: obstruction, gastric irritation
* Metabolic: hypercalcemia, uremia
* Drugs induced: opioid
* Treatment related: chemotherapy, radiotherapy
* CNS: brain / leptomeningeal metastases

Management:
* Treat reversible causes
Antiemetics:
* Prokinetics (metoclopramide)
* Central anti-dopaminergic drugs (haloperidol)
* Brain metastases: dexamethasone
* Chemo-induced 5HT3 antagonist (e.g. ondansetron), neurokinin-1 antagonist (aprepitant), antipsychotics (olanzapine)

30
Q

Palliative care intervention

  • Determinants of invasive intervention
A

Invasiveness of intervention should take account of the overall prognosis and the reversibility of underlying condition

e.g. Single hilar met causing CBD obstruction (by CA ampulla of vater) versus multiple liver met with mild bilateral intra-hepatic duct dilatation carries very different prognosis

Need careful assessment in every patient. No single straight forward answer

31
Q

Advance directive

Function
Scope of discussions

A

Function: Plan on future end-of-life medical and personal care options for terminally ill patients, or make advance directive/ refusing life-sustaining treatment (e.g. CPR, continue with artificial nutrition/ hydration)

Involvement of patient, family and healthcare worker

Patient mentally incapable of making health care decisions.

32
Q

Timing for advanced directive planning

A
  • Significant decline in functional status and level of physical activity, or need to be institutionalized;
  • Considerable discomfort in terms of physical and psychological
    symptoms, and social anxiety;
  • Obvious commencement of the final stage of disease
  • Futility of disease targeted treatments established and transition
    from curative treatment to palliative care.
33
Q

DNR/ DNAR/ DNACPR

  • Definition
A

Do Not Resuscitate (DNR), Do Not Attempt Resuscitation (DNAR), and Do Not Attempt Cardiopulmonary Resuscitation (DNACPR)

  • CPR is not to be initiated on the patient, based on prior deliberations between the patient/family and the healthcare team.
  • Does not automatically imply whether the patient will
    or will not be receiving other life-sustaining treatments.
34
Q

Protocol for breaking bad news

A
35
Q

Anorexia in terminal illness

Causes

Management

A

Causes: : pain, depression, dysphagia, nausea, cancer cachexia, oral pain, odour

Management:
* treat reversible causes
* maintain good oral hygiene
* frequent small meals
* Psychological support
* Acknowledge the worries of families
* Dietary supplement: no evidence to improve cachexia

Drugs: Appetite stimulants (cannot reverse cachexia)
- Cortiosteroid: dexamethasone 2-4mg daily, 1 week trial
- Progestogen

Alternative feeding:
- Parental nutrition
- Tube feeding

36
Q

Malignant IO in terminal cancer

Causes
Treatment options

A

Most commonly associated with GI tract cancers and cancers causing peritoneal metastases

Most important diagnosis:
* Single-level obstruction with good performance status: consider bypass surgery / colostomy / stenting
* Multiple-level obstruction or patient with poor performance status: comfort care

Medical symptomatic treatment
* Anticolinergic / antisecretory: hyoscine infusion, ocetreotide
* Parental analgesics (IV or subcutaneous) morphine

NG tube decompression: only for high volume vomiting

37
Q

Delirium in terminal cancer

Causes
Precipitation factors
Treatment

A

Causes:
1. Iatrogenic: opioid, anticholinergic, steroid, sedatives
2. Uncontrolled symptoms: pain, urinary retention
3. Infection / sepsis
4. Metabolic: hypercalcemia, hyponatremia, CO2 retention
5. CNS: brain metastases
6. Terminal end-of-life stage

Exacerbated by: change in environment, insomnia, fear, anxiety

Treatment:
* Identify all reversible causes
* Calm reassurance to patient and family
* Review drug chart! Withhold potentially related drugs
* Drug treatment after reviewing all reversible causes: Haloperidol, Chlorpromazine, Midazolam

38
Q

End-of-life S/S

A

Impending death
* Profound weakness – usually the patient can’t get out of bed and has trouble moving around in bed
* Disinterest in food and fluid intake for days
* Trouble swallowing pills and medicines
* More drowsiness
* Confusion about time, place, or people